Efficacy of Verciguat in TR and RV Failure

A phase 4 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 100 participants.

Also called NCT07668739

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 100 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07668739
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
South Korea (from the registry)
Registry status
  • Not yet recruiting (from the registry)

Technical summary

Registry record NCT07668739. Randomized; no masking; primary purpose treatment. Start 2026-07-01 (anticipated); primary completion 2028-05-31 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy of Verciguat in TR and RV Failure
Acronym
VERT-HF
Condition
HFrEF
Condition
Tricuspid Regurgitation (TR)
Intervention (Drug)
Vericiguat
Lead sponsor
Daejeon St. Mary's hospital (class: other)
Collaborator
Seoul St. Mary's Hospital (class: other)
Collaborator
Uijeongbu St. Mary Hospital (class: other)
Collaborator
Incheon St.Mary's Hospital (class: other)

Record details

Record id
cardio:ct-nct07668739
Content hash
a6c971e11f1fb4cb3c3166d168255fd0c0a48be2ae14268e3e6ad8437a263c57